Sponsored Symposia Programme

13:00-14:00, room HELSINKI 1, Theramex – Sponsored Symposium

VVA/GSM: current and new advance?

Chair: Tim Hillard, United Kingdom

• VVA/GSM – What do we know?
  Thomas Römer, Germany
• Prasterone – A novel approach to the treatment of moderate to severe VVA/GSM
  Tim Hillard, United Kingdom
• Questions and answers
  All

13:00-14:00, room HELSINKI 2, Max Zeller Söhne AG – Lunch Symposium

Healthy aging in menopause: Focus on weight and metabolism

Chair: Veronika Butterweck, Switzerland

• Impact of menopause on metabolism, body weight, and body composition
  Petra Stute, Switzerland
• Bioenergetic switches by Cimicifuga racemosa extract Ze450 prevent oxidative dysregulation and mitochondrial damage in neurons and liver cells
  Carsten Culmsee, Germany

09:15 – 10:15, room HELSINKI 1, Pantarhei Oncology – Sponsored Symposium

Treatment of Breast and Prostate Cancer with the Fetal Estrogen Estetrol

Chair: Tommaso Simoncini, Italy & Yvette Zimmerman, The Netherlands

• The profile of the fetal estrogen estetrol (E4)
  Herjan Coelingh Bennink, The Netherlands
• Treatment of advanced breast cancer with E4
  Hans Georg Lenhard, Germany 
• Treatment of advanced prostate cancer with E4
  Frans Debruyne, The Netherlands

09:15 – 10:15, room HELSINKI 2, Shionogi- Sponsored Meet-the-Expert Symposium

Managing vulvovaginal atrophy (VVA) without hormones: changes in the tissues of the vagina and the vulvar vestibule and their impact on dyspareunia and quality of life

Chair: Santiago Palacios (Spain)

• Welcome and Introduction
  Santiago Palacios, Spain
• Effects of Ospemifene on the vulvar and vaginal tissue in women with VVA
  Cristina Meriggiola, Italy
• Vulvar vestibular effects of Ospemifene: reducing the sensitivity of sensory nerve fibres
  Filippo Murina, Italy
• VVA in clinical practice: case studies
  Carmen Pingarron, Spain
• Q&A with audience, summary and close
  Santiago Palacios, Spain

12:30 – 14:00, 16.05.2019, room HELSINKI 1, Mylan – Lunch Symposium

The progestin makes the difference. Role of Dydrogesterone in HRT

Chair: Nick Panay, United Kingdom

• “Modern” hormone therapy in menopause – Are we ready to change our approach?
  Nick Panay, United Kingdom
• Management of menopause – Women’s fears and women’s needs
  Katrin Schaudig, Germany
• Progestogens: Basic mode of action and differences
  Christian Egarter, Austria
• Dydrogesterone beyond HRT indications. Review of the clinical data
  Petra Stute, Switzerland

08:00 – 09:00, room HELSINKI 1, Schaper & Brümmer – Sponsored Symposium

Yes, no, maybe? Time for consensus: An update on black cohosh (Cimicifuga racemosa) for climacteric symptoms

Chair: Alfred O. Mueck, Germany & Xiangyan Ruan, China

• Clinical efficacy and safety of isopropanolic Cimicifuga racemosa extract (iCR)
  Camil Castelo-Branco, Spain
• Benefit-risk profile of iCR with and without St. John’s Wort in breast cancer patients
  Harald Meden, Switzerland
• Latest insights into iCR’s mode of action
  Petra Stute, Switzerland

08:00 – 09:00, 17.05.2019, room HELSINKI 2, Mithra- Sponsored Symposium

Estetrol (E4) – The eight o’clock news you need to take back home

Chair: Ulysse Gaspard, Belgium

• Welcome and introduction
  Ulysse Gaspard, Belgium
• E4 is the first native estrogen with selective tissue action
  Jean-Michel Foidart, Belgium
• The latest E4 clinical data – Are we heading towards a new generation hormonal therapy?
  Sven O. Skouby, Denmark
• Questions and answers
  All

12:30 – 14:00, room HELSINKI 2, DR. KADE / Besins – Lunch Symposium

HRT – Chancen nutzen, Risiken minimieren

Chair: Alfred O. Mueck, Germany & Joseph Neulen, Germany

• HRT kann mehr als die Behandlung von Hitzewallungen
  Petra Stute, Switzerland
• Risiken durch eine natürliche HRT erfolgreich minimieren
  May Ziller, Germany

12:30 – 13:00, EMAS ARENA, Sérélys Pharma – Sponsored Symposium

Effect of a composition of purified and specific cytoplasm extracts of pollen (PSCEP), pumpkin seed extract and vitamin E (Femaxeen®) on women with urinary incontinence: a randomized, double-blind, placebo-controlled clinical trial

Chair: Santiago Palacios, Spain

12:30-13:15, Lindau Room 3, Alma Lasers – Sponsored Workshop

Dr. Elke Heßdörfer, Urogynecologist and Alma Lasers present the “Femilift”, a unique Pixel-CO2  technology.
The theory and practice behind the treatment of GSM (vaginal dryness, SUI, Dyspareunia, etc.). My experience and results followed by Handson session with the system.

13:15 – 14:00, EMAS ARENA, Fotona – Sponsored Lunch Symposium/Workshop

Non-ablative FotonaSmooth ErYAG laser – the safe and efficacious option for GSM, SUI, POP and VRS

Chair: Marco Gambacciani, Italy

Long-term efficacy for GSM treatment and the use of laser in breast cancer survivors
Marco Gambacciani, Italy
Use of FotonaSmooth Er:YAG laser for treatment of SUI, POP and VRS
Ivan Fistonic, Croatia
Video workshop with live commentary